In response to the concerns over the link between Xarelto and uncontrollable bleeding, Andrus Wagstaff PC is investigating potential lawsuits for victims.
Manufactured and marketed by Jansen Pharmaceuticals, a Johnson & Johnson Company, Xarelto is an anticoagulant blood thinner designed to prevent the formation of blood clots. In 2011, the U.S. Food and Drug Administration (FDA) first approved Xarelto (rivaroxoaban), and it is indicated to reduce the risk of strokes, deep vein thrombosis (DVT), pulmonary embolism (PE), and blood clots in patients who have undergone hip or knee replacement surgery. The drug is also commonly prescribed to reduce the risk of stroke in patients with a certain type of heart rhythm disorder. However, it has not been approved to reduce blood clots in patients with coronary artery disease.
Xarelto carries the risk of internal bleeding side effects. However, Xarelto internal bleeding side effects cannot be controlled or reversed by physicians resulting in the drug being potentially more dangerous than other anticoagulants.
There have been more than 2,100 total reports to the FDA involving Xarelto, with 1,821 listing the drug as the primary suspect for an adverse event. The FDA has announced that it is currently in the process of evaluating bleeding events in patients being treated with Xarelto to determine whether the risks outweigh the benefits of the drug.
Andrus Wagstaff PC is investigating potential claims in regards to Xarelto and is accepting referrals. Please contact us using the online form to the left so that we may better evaluate your claim.